Cimzia — Medica

Initial criteria

• Patient meets the standard Inflammatory Conditions – Cimzia Prior Authorization Policy criteria
• Patient is currently receiving Cimzia and meets condition-specific trial requirements as outlined (two of tocilizumab subcutaneous product, Enbrel, an adalimumab product, Rinvoq/Rinvoq LQ, Xeljanz/XR, Taltz, Otezla, Skyrizi subcutaneous, ustekinumab subcutaneous product, Tremfya subcutaneous, or Zymfentra as appropriate)

Approval duration

1 year